Certara, Inc. (CERT)

Certara's stock price declined by 39.44% between March 25, 2025, and March 24, 2026, with a 52-week range of $5.60 to $15.38. Key events impacting the stock include the Q3 2025 earnings report noting variability in Tier 1 services bookings, the Q4 2025 earnings report with mixed financial performance and cautious 2026 guidance, the new CEO's focus on operational overhaul, and the Certara Simcyp Simulator results replacing ten human trials for a CML therapy.

Specific demand seasonality for Certara's products and services is not explicitly detailed. Management cited variability in Tier 1 services bookings, suggesting inconsistent demand influenced by external factors. The continuous nature of drug development suggests steady underlying demand for core biosimulation software, while project-based consulting services may fluctuate. Demand is also driven by increasing global regulatory support and advancements in technology, with ongoing investments in R&D aiming to drive consistent demand and growth.

Certara, Inc. is a global leader in biosimulation software and technology-enabled services within the Technology Services sector, focusing on Healthcare and Drug Delivery. The company accelerates medicine development through quantitative pharmacology, real-world evidence, AI, and machine learning. Certara's offerings include software tools like Phoenix WinNonlin, Simcyp Simulator, Cognigen, Certara.AI, GlobalSubmit eCTD Software, Pinnacle 21, D360, Chemaxon, BaseCase, and SEND Explorer®. Services include regulatory strategy support, MIDD consulting, real-world data analytics, bespoke simulation projects, biometrics & data science, drug development support, and market access consulting.

Certara has a global presence with offices and development centers across North America, Europe, and the Asia Pacific region, serving clients in over 70 countries. Key locations include Durham, NC; Clayton, MO; Radnor, PA in North America; Berlin, Germany; Budapest, Hungary; Luxembourg; and Oss, Netherlands in Europe; and Tokyo, Japan; Seoul, Republic of Korea; and Makati City, Philippines in Asia-Pacific. The Americas are also a key revenue-generating market.

Certara maintains a strong brand reputation within the life sciences industry for its biosimulation software and services. Its software products are licensed by 23 global drug regulatory agencies, and its solutions are cited in over 33,000 peer-reviewed articles. The company emphasizes innovation in AI and machine learning, and its greenhouse gas emissions reduction target was approved by the Science Based Targets initiative. However, the company has faced challenges including cautiousness among large pharma customers, macroeconomic headwinds, and the ongoing strategic review of its regulatory writing and operations business.

Certara has a diverse ownership structure, with institutional investors holding a significant portion. As of March 24, 2026, there were 322 institutional owners holding 143,718,884 shares, representing 62.38% to 79.96% of the company's stock. Insiders own around 2.28%, and public companies and individual investors hold about 17.59% to 17.76%. Major institutional owners include Wasatch Advisors Inc, BlackRock, Inc., and Vanguard Group Inc.